Professor Maria Angelica Selim, MD, highlighted the valuable role pathology plays in patient care during the Duke Cancer Institute’s (DCI) Hilliard Seigler Duke Melanoma Consortium, held on May 15, 2026, at the Trent Semans Center in Durham, North Carolina. Drawing from multidisciplinary tumor board cases, Selim demonstrated how pathology informs accurate diagnosis, integrates clinical context, and supports treatment decisions, ultimately advancing more personalized cancer care.
The event also featured patients and survivors who shared their experiences with diagnosis, treatment, and survivorship, underscoring the importance of strong communication and collaboration among clinicians, researchers, patients, and families. They underscored the profound human impact of team-based cancer care.
DCI’s Melanoma Consortium brings together experts across disciplines to advance research and care for melanoma and other advanced skin cancers. Each year, the meeting highlights innovations in diagnosis and treatment while honoring the legacy of former Duke Professor of Surgery and Professor of Immunology Hilliard Seigler, MD. It offers a unique, patient-inclusive forum that showcases how complex cases are evaluated through a multidisciplinary approach.
